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BACKGROUND/PURPOSE: The emergence of multiple drug resistance in Enterobacteriaceae is of par-
ticular concern. The aim of this study was to evaluate the antimicrobial susceptibility and screen for the 
ampC gene in three members of the Enterobacteriaceae family (Enterobacter cloacae, Citrobacter freundii, and 
Serratia marcescens) found at Taichung Veterans General Hospital during the past 5 years using multiplex 
polymerase chain reaction (PCR).
METHODS: The susceptibility of thirty isolates from each of the three Enterobacteriaceae family members 
to five antimicrobial agents (ceftazidime, flomoxef, imipenem, moxifloxacin, and colistin) was assessed. 
The susceptibility was analyzed by disk diffusion, screening and confirmatory tests for extended-spectrum 
β-lactamases (ESBL) and minimum inhibitory concentration tests according to the recommendations of 
the Clinical and Laboratory Standards Institute. The detection of ampC genes (3 families, including DHA, 
EBC and CIT) was performed by multiplex PCR. To detect the coexistence of ESBL genes, PCR was per-
formed using five primer pairs: TEM, SHV, SHV-5, CTX-M-3, and CTX-M-14.
RESULTS: Of the 90 isolates, 53 (58.9%) were positive in the screening test for ESBL. Resistance genes 
were detected in 12 (22.6%) of these isolates: ampC gene of DHA type in one E. cloacae isolate and EBC type 
in three E. cloacae isolates; ampC gene of CIT type in four C. freundii isolates; CTX-M-3-like in one C. freundii 
isolate and one S. marcescens isolate; TEM in three E. cloacae isolates, three C. freundii isolates and two 
S. marcescens isolates; SHV in one C. freundii isolate.
CONCLUSION: Antibiotic phenotypes cannot accurately distinguish the resistance mechanisms caused 
by ampC or ESBL, and especially in ESBL-ampC combinations. However, PCR is a useful technique for the 
identification of the different types of resistance genes.
KEYWORDS: AmpC, Citrobacter, Enterobacter, extended-spectrum β-lactamases, Serratia
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Introduction
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Entero-
bacter cloacae, Serratia marcescens, and Citrobacter freundii ac-
count for the majority of Enterobacteriaceae isolated from 
clinical specimens. The emergence of multidrug resistant 
Enterobacteriaceae is of particular concern because of the 
potential for widespread dissemination, and difficulties 
in treating infected patients.1,2
The majority of plasmid-mediated ampC genes 
are found in nosocomial isolates of E. coli and K. pneumo-
niae. E. cloacae, C. freundii, S. marcescens, and Morganella 
morganii are characterized by chromosomally encoded 
AmpC β-lactamases and possess the ability to develop re-
sistance upon exposure to broad-spectrum cephalosporins.3 
These genes can confer broad-spectrum resistance to 
most β-lactams (other than cefepime and carbapenems) 
and hence pose a major therapeutic challenge.4,5 Accord-
ing to the criteria of the Clinical and Laboratory 
Standards Institute (CLSI),6 all isolates with minimum 
inhibitory concentrations (MICs) ≥ 2 μg/mL for ceftazi-
dime, ceftriaxone, cefotaxime or aztreonam are potential 
extended spectrum β-lactamase (ESBL) producers. The 
CLSI recommends that a confirmatory clavulanic acid 
inhibition test be performed on these “screen test”-positive 
clinical isolates before reporting the susceptibility results 
for cephalosporins, and aztreonam.6 Enterobacteriaceae iso-
lates with a positive screen test of ESBL phenotype, but a 
negative ESBL confirmatory test, are potential candidates 
for production of the AmpC enzyme, either mediated by 
chromosomal depression or transferred by a plasmid.7 
Many clinical microbiologists appear to be unaware of the 
presence of plasmid-mediated AmpC β-lactamase enzymes 
in resistant isolates because phenotypic detection can be 
difficult and the strains may be misidentified as ESBL 
producers.8 Many methods for the detection of ESBLs, 
plasmid-mediated AmpC β-lactamases, and carbapenemases 
have been proposed. However, some of these procedures 
are technically demanding and time-consuming, others 
are hard to interpret, and still others require specialized 
reagents or reagents that are difficult to obtain.9
The presence of multiple β-lactamases within one or-
ganism (e.g. multiple ESBLs or ESBL-AmpC combina-
tions) can make phenotypic identification difficult.10 
Unfortunately, for these reasons, plasmid-mediated AmpC 
β-lactamase resistance goes undetected in most clinical 
laboratories.10
A multiplex polymerase chain reaction (PCR) method 
has been developed using six primer pairs to detect plasmid-
mediated ampC genes. This technique is capable of identi-
fying the family-specific ampC gene responsible for AmpC 
β-lactamase expression.11
Seventeen of 110 (15.5%) E. cloacae isolates from a Central 
Taiwan hospital were identified as ESBL-producers (pre-
dominantly SHV-12, with some isolates also producing 
CTX-M-3 and CTXM-9).7 Fifteen of 123(12.2%) S. marces-
cens isolates from the same hospital were ESBL-producers, 
and all carried CTX-M-3.12 In a study from Northern 
Taiwan, SHV-12 was present in 26 isolates of E. cloacae, 
with the coexistence of CTX-M-3 in three of the isolates.13 
However, studies of the AmpC β-lactamases present in 
Enterobacteriaceae has not been performed in Taiwan. 
The aim of this study was to evaluate the antimicrobial 
susceptibility of three members of the Enterobacteriaceae 
family (E. cloacae, C. freundii, and S. marcescens) found in 
Taichung Veterans General Hospital (TCVGH) during the 
past 5 years, and to screen for the related ampC resistant 
genes using multiplex PCR.
Materials and Methods
Isolates
Thirty isolates of each of the E. cloacae, C. freundii, and 
S. marcescens were collected from the Microbiology Labora-
tory of TCVGH between 2003 and 2007. All isolates were 
collected from blood specimens.
Screening test of ESBL phenotype
Screening tests were performed on all the isolates as fol-
lows: the MICs for ceftazidime were determined using the 
E-test (AB BIODISK, Solna, Sweden). Disk diffusion tests 
for ceftazidime and cefotaxime were performed according 
to CLSI recommendations.6 An isolate was considered 
positive if the MIC for ceftazidime was ≥ 2 μg/mL, if the 
inhibition zone for ceftazidime was ≤ 22 mm, or the inhi-
bition zone for cefotaxime was ≤ 27 mm.
Confirmatory test
All isolates with a positive screening test were further 
tested using the confirmatory test according to CLSI 
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recommendations.6 An isolate was considered to have a 
positive confirmatory test if it showed a ≥ 5 mm increase 
in zone diameter for either ceftazidime or cefotaxime tested 
in combination with clavulanic acid versus its zone when 
tested alone.
Susceptibility test
The MICs of five antimicrobial agents; flomoxef (Shionogi, 
Osaka, Japan), imipenem (MSD, Rahway, NJ, USA), moxi-
floxacin (Bayer, Leverkusen, Germany), colistin (TTY, 
Hsinchu, Taiwan) and ceftazidime (GSK, UK) were assessed 
using the broth microdilution method according to CLSI 
recommendations.6 The antibiotics were serially diluted 
two-fold in 50 μL of cation-adjusted Mueller-Hinton 
broth. The final range of antibiotic concentrations was 
0.01–256 μg/mL. The bacterial suspension was prepared 
from actively growing bacteria in 5 mL of cation-adjusted 
Mueller-Hinton broth, and diluted to a bacterial cell den-
sity of 106 colony forming units (CFU)/mL. Five μL of 
bacterial suspension was then added to wells containing 
100 μL of serially diluted antimicrobial agents to yield 
a final inoculum of approximately 5 × 104 CFU/mL. The 
MICs were read after overnight incubation (18–24 hours) 
at 35ºC. All MICs were determined in duplicate. E. coli 
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 
were used as the quality control strains.14
Multiplex PCR protocol for detection of AmpC genes
Total bacterial DNA was prepared using guanidinium thio-
cyanate as previously described.11,15 PCR was performed 
in a final volume of 50 μL. The primers used for PCR am-
plification are listed in Table 1.11 Each reaction contained 
45 μL of the master mix [20 mM Tris-HCl (pH 8.4), 50 mM 
KCl, 0.2 mM dNTPs, 1.5 mM MgCl2, 0.6 μM forward and 
0.6 μM reverse primers MOXM, CITM, CITM, DHAM, 
and DHAM; 0.5 μM primers ACCM, ACCM, EBCM, and 
EBCM, 0.4 μM primers FOXM and FOXM, and 1.25 U of Taq 
DNA polymerase (QIAGEN, GmbH, Hilden, Germany)] 
and 5 μL of template DNA. PCR mixtures with the addi-
tion of water in place of template DNA were used as nega-
tive controls. The PCR program consisted of an initial 
denaturation step at 94ºC for 3 minutes, followed by 
25 cycles of DNA denaturation at 94ºC for 30 seconds, 
primer annealing at 64ºC for 30 seconds, and primer ex-
tension at 72ºC for 1 minute. After the last cycle, a final 
extension step at 72ºC for 7 minutes was added. PCR 
products (5 μL) were resolved in 2.5% agarose gel (Bio-
Rad, Hercules, California, USA). Gels were stained with 
10 μg/mL ethidium bromide and visualized by UV transil-
lumination. A 100 bp DNA ladder (Gene DireX, USA) was 
used.16
Multiplex PCR for the detection of ESBL genes
To detect the coexistence of ESBL genes, three primer pairs 
for screening the blaTEM, blaSHV, and blaCTX-M genes were 
used in the PCR reaction.17 For further identification of 
the most prevalent ESBL types, the following primer pairs 
were used: CTX-M-3,18,19 CTX-M-14,19 and SHV-5.20
Results
The antibiotic susceptibility of E. cloacae, C. freundii and 
S. marcescens is summarized in Table 2. Ceftazidime had 
variable activity against E. cloacae, C. freundii and S. marces-
cens with susceptibility rates of 53%, 60%, and 100%, re-
spectively. Flomoxef was less active, with susceptibility 
rates of 10%, 10%, and 57%, respectively. Imipenem was the 
most active agent, with susceptibility rates of 97%, 100%, 
and 87%, respectively. Moxifloxacin had moderate activ-
ity, with susceptibility rates of 53%, 87%, and 67%, respec-
tively. Colistin was the least active, with susceptible rates 
of 0%, 50%, and 0%, respectively.
Table 3 shows the number of isolates with the ESBL 
phenotype and related resistant genes. Nineteen E. cloacae 
isolates had a positive screening test for cefotaxime by the 
disk diffusion. Six E. cloacae isolates had a positive ESBL 
confirmatory test, and one of these six isolates carried 
ESBL genes. Thirteen E. cloacae isolates had a negative ESBL 
confirmatory test, and two of these carried ESBL genes. Only 
three of 19 E. cloacae isolates were detected by ESBL con-
firmatory test but four isolates were noted by the multiple 
PCR test in the following study (Table 4). Eighteen iso-
lates had a positive screening test for cefotaxime by disk 
diffusion, while 16 were positive for by ceftazidime broth 
microdilution. Five C. freundii isolates had a positive ESBL 
confirmatory test, and two carried an ESBL gene. Thirteen 
C. freundii isolates had a negative ESBL confir matory test, 
and one of these 13 isolates carried ESBL genes. Four of 
18 C. freundii isolates contained ampC genes. Among the 
30 S. marcescens isolates, 16 had a positive screening test 
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for cefotaxime by disk diffusion, while one had a positive 
screening test for ceftazidime by broth microdilution. 
Four S. marcescens isolates had a positive ESBL confirma-
tory test, and two of them carried ESBL genes. Twelve 
S. marcescens isolates had a negative ESBL confirmatory 
test, and no ESBL genes were detected. None of these 16 
S. marcescens isolates carried ampC genes.
The isolates of E. cloacae, C. freundii, and S. marcescens 
with their resistance genes and related MICs for each of 
the five antibiotics are listed in Table 4. The E. cloacae iso-
late, E2, had an AmpC enzyme of the DHA type, and the 
TEM gene. The E. cloacae isolates, E3 and E14, had AmpC 
enzymes of the EBC type. The E. cloacae isolate, E5, had an 
AmpC enzyme of the EBC type, and the TEM gene. The 
E. cloacae isolate, E19, had only the TEM gene. All four of 
these isolates had low to high level resistance to ceftazi-
dime with MICs ranging from 2 μg/mL to > 256 μg/mL, 
and high level resistance to flomoxef with MICs ranging 
from 128 μg/mL to > 256 μg/mL. The C. freundii isolate, 
C6, had both the TEM and SHV genes. Isolates, C16, C17, 
had an AmpC enzyme of the CIT type only and isolate C22 
had an AmpC enzyme of the CIT type, and the TEM and 
CTX-M-3-like genes. Isolate C25 had an AmpC enzyme of 
the CIT type and the TEM gene. All five isolates had low to 
medium level resistance to ceftazidime with MICs rang-
ing from 2 μg/mL to > 32 μg/mL, and intermediate to 
medium level resistance to flomoxef with MICs ranging 
from 32 μg/mL to 128 μg/mL. The S. marcescens isolate, S5, 
had only the TEM gene. The S. marcescens isolate, S7, had 
both the TEM and CTX-M-3-like genes. These two isolates 
were susceptible to ceftazidime with MICs ranging from 
1 μg/mL to 2 μg/mL, and were also susceptible to flo-
moxef with MICs ranging from 2 μg/mL to 16 μg/mL. 
Discussion
Colistin was less active against the three species of 
Enterobacteriaceae in this study, although it displayed good 
activity against Acinetobacter spp., Klebsiella spp., and E. coli 
in the previous study.21 In a recent report, Enterobacter spp. 
showed low rates of susceptibility to the five fluoroqui-
nolones: ciprofloxacin, ofloxacin, norfloxacin, levofloxacin, 
and gemifloxacin.22 In contrast, moxifloxacin showed 
moderate activity against the three species in this study, 
although cross-resistance was common in the ESBL-
producing Enterobacteriaceae. 
The E19 isolate of E. cloacae carried the TEM gene alone, 
and was resistant to both ceftazidime and flomoxef 
Table 1. Primers used for amplification of AmpC
Gene
 Accession 
Primer Sequence
 Nucleotide 
Target(s)
 Product
 numbera   positions  size (bp)
MOXM D13304 forward 5-GCT GCT CAA GGA GCA CAG GAT-3 358–378 MOX-1, MOX-2, CMY-1,  
520
  reverse 5-CAC ATT GAC ATA GGT GTG GTG C-3 877–856 CMY-8 to CMY-11
CITM X78117 forward 5-TGG CCA GAA CTG ACA GGC AAA-3 478–498 LAT-1 to LAT-4,  
462
  reverse 5-TTT CTC CTG AAC GTG GCT GGC-3 939–919 CMY-2 to CMY-7, BIL-1
DHAM Y16410 forward 5-AAC TTT CAC AGG TGT GCT GGG T-3 1,244–1,265 
DHA-1, DHA-2
 
405
  reverse 5-CCG TAC GCA TAC TGG CTT TGC-3 1,648–1,628
ACCM AJ133121 forward 5-AAC AGC CTC AGC AGC CGG TTA-3 861–881 
ACC
 
346
  reverse 5-TTC GCC GCA ATC ATC CCT AGC-3 1,206–1,186 
EBCM M37839 forward 5-TCG GTA AAG CCG ATG TTG CGG-3 1,115–1,135 
MIR-1T, ACT-1
 
302
  reverse 5-CTT CCA CTG CGG CTG CCA GTT-3 1,416–1,396  
FOXM X77455 forward 5-AAC ATG GGG TAT CAG GGA GAT G-3 1,475–1,496 
FOX-1 to FOX-5b
 
190
  reverse 5-CAA AGC GCG TAA CCG GAT TGG-3 1,664–1,644
aSequence from Genebank and used for primer design.
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with MICs > 256 μg/mL. Flomoxef was less active than 
ceftazidime against both E. cloacae and C. freundii in this 
study. Flomoxef is an oxacephem antibiotic, and is sup-
posed to be active against Enterobacteriaceae, producing a 
TEM β-lactamase. Further work is necessary to determine 
whether this was a new β-lactamase capable of hydrolyz-
ing cephamycins.
Among the 19 E. cloacae isolates with a positive screen-
ing test for ESBL, four carried ampC genes of either the 
DHA or EBC types. Among the 18 C. freundii isolates with 
a positive screening test for ESBL, four carried an ampC 
gene of the CIT type. All these isolates showed high-level 
resistance to flomoxef (MIC > 128 mg/mL). Hence, flo-
moxef resistance in combination with a positive ESBL 
screening test could serve as sensitive indicator of AmpC 
enzyme production.
The screening and confirmatory tests have proven to 
be reliable for detecting the majority of conventional 
ESBLs, especially for variants of the TEM and SHV en-
zyme classes. We have tried our best to analyze the differ-
ent ESBL types using six different primer pairs. The SHV 
gene was found in a C. freundii isolate, the CTX-M-3-like gene 
was found in a C. freundii isolate and in a S. marcescens isolate. 
Previous studies show that SHV-12 is the predominant 
E. cloacae ESBL type in Taiwan.7,13,23 In contrast, the per-
centage of SHV genes found in this study was less than 
that found in previous studies. This discrepancy could be 
due to the limited number of isolates used in this study, 
or to the different distribution of ESBL types in different 
hospitals. The TEM-1 gene was found to coexist with the 
SHV-12 gene in the 13 E. cloacae isolates in studies by Yu 
et al and Ma et al.7,23 Three E. cloacae isolates in this study 
were found to have the TEM class of β-lactamases. Identi-
fication of TEM types could be made by isoelectric focus-
ing (IEF) and sequence analysis. However, this was beyond 
the scope of this study.
In a recent study conducted by the SENTRY Asia-
Pacific surveillance program,24 52 E. coli isolates and 68 
K. pneumoniae isolates with negative ESBL confirmatory 
tests, as well as a comparable number of isolates with con-
firmed ESBL-positive tests, were examined for the presence 
of the TEM, SHV, plasmid-borne ampC, and CTX-M genes. 
Interestingly, 62% of non-confirmed E. coli isolates and 
75% of non-confirmed K. pneumoniae isolates harbored a 
plasmid-borne AmpC enzyme of the CIT or DHA type.
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It is not uncommon for Enterobacteriaceae to carry 
multiple resistance genes. Among the 52 E. coli isolates 
with a non-confirmed ESBL test in the previously men-
tioned SENTRY Asia-Pacific surveillance program,24 26 
isolates (50%) carried AmpC + TEM enzymes. Similarly, 
this study showed that one isolate of E. cloacae had DHA + 
TEM enzymes while a second had EBC + TEM enzymes; 
two isolates of C. freundii had CIT + TEM + CTX-M-3-like 
enzymes, and CIT + TEM enzymes respectively. For the 
Enterobacteriaceae isolates carrying both the ESBL and 
AmpC enzymes, the phenotype appeared to be a positive 
screening test and negative confirmatory test. The AmpC 
enzyme can hydrolyze clavulanic acid, and thus make 
the confirmatory test negative. We also found 12 isolates 
of the three species with a positive screening test in which 
we were unable to detect any β-lactamase genes. These 
Table 3. Number of isolates with the extended spectrum β-lactamase phenotype and related resistant genes
 E. cloacae (n = 30) C. freundii (n = 30) S. marcescens (n = 30)
Positive screening test
 Ceftazidimea 13 14  3
 Cefotaximeb 19 18 16
 Ceftazidimec 15 16  1
ESBL confirmatory test
 PCT (gene)  6  5  4
  With ESBL genes  1  2  2
  With ampC genes  0  1  0
 NCT (gene) 13 13 12
  With ESBL genes  2  1  0
  With ampC genes  3  3  0
aDisk diffusion (inhibition zone ≤ 22 mm); bdisk diffusion (inhibition zone ≤ 27 mm); cbroth dilution (MIC ≥ 2 μg). ESBL = extended spectrum 
β-lactamase; PCT = positive confirmatory test; NCT = negative confirmatory test. 
Table 4. The Enterobacter cloacae, Citrobacter freundii, and Serratina marcescens isolates with their resistance genes and related minimum 
inhibitory concentrations for the five antibiotics
 E. cloacae C. freundii S. marcescens
 E2 E3 E5 E14 E19 C6 C16 C17 C22 C25 S5 S7
Resistance genes
 ampC DHA EBC EBC EBC − − CIT CIT CIT CIT  
 ESBL TEM − TEM – TEM TEM/SHV − − TEM/ TEM TEM TEM
         CTX-M-3-like   CTX-M-3-like
Confirmatory test − −  +  − − − − − − −  +   + 
MICs (μg/mL)
 Ceftazidime  2 16   256 0.25 > 256 2 32 2  8 8  2  1
 Flomoxef 128 > 256 > 256 256 > 256 32 128 32 128 64 16  2
 Imipenem  2 2  1  2  1 1 1 2  1 1  4  2
 Moxifloxacin  1 2  8 64 16 0.125 0.125 0.5  16 0.06 16  2
 Colistin  8  > 256 16 > 256 16 8 2 2  2 4 > 256 256
MIC = Minimum inhibitory concentration; ESBL = extended spectrum β-lactamase.
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isolates may produce enzymes not covered by the selected 
primer pairs, or may have mutations affecting the porin 
channels responsible for antimicrobial uptake.
The prevalence of AmpC-mediated resistance world-
wide is not well known due to the limited number of sur-
veillance studies for AmpC-producing isolates and the 
difficulty in accurately detecting these resistance mecha-
nisms.11 The MYSTIC programs in Europe and the United 
States reported that the rates of ampC genes were much 
higher in Citrobacter spp. (9–25%) and Enterobacter spp. 
(13.8–29.2%) than in E. coli (0.6–2.8%) or Klebsiella spp. 
(0.5–4.5%).25 In our study, ampC genes were detected in 
13.3% of E. cloacae and C. freundii isolates, but not in any of 
the S. marcescens isolates.
In a previous study, the coexistence of AmpC (DHA-1, 
CMY-2, or CMY-8) and ESBLs (CTX-M and/or SHV) was de-
tected in 35 of 99 clinical K. pneumoniae isolates resistant 
to cefoxitin and extended-spectrum cephalosporins.26 
The CMY-2-like β-lactamase was detected in 127 of 291 
(43.6%) E. coli isolates. Among 282 K. pneumoniae isolates, 
the CMY-2-like and DHA-1-like β-lactamases were detected 
in 10 (3.5%) and 31 (11.0%) isolates, respectively.27
The CIT primer pair amplifies the family-specific 
genes LAT-1 to LAT-4, CMY-2 to CMY-7, and BIL-1. The 
DHA primer pair amplifies the family-specific genes 
DHA-1 and DHA-2.11 In our study, both CIT and DHA were 
detected in those resistant isolates by the screening primers. 
However, the specific subtypes need to be sequenced further, 
or subjected to IEF.
In summary, Enterobacteriaceae carry AmpC or ESBL 
enzymes that can be identified by a positive screening test 
and elevated MIC results. Positive confirmatory tests for 
ESBL indicate ESBL production. However, negative con-
firmatory tests do not exclude ESBL, but indicate the 
presence of ampC or a combination of ampC and ESBL. 
Antibiotic phenotypes cannot accurately distinguish be-
tween the resistance mechanisms caused by ampC or ESBL, 
especially where ampC-ESBL combinations are concerned. 
However, PCR is a useful technique for the identification of 
the different types of resistance genes.
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